ALNY News and Press, Alnylam Pharmaceuticals Inc. From 11/21/23

2023-11-21 00:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-15 01:56:28 ET Summary Baillie Gifford's 13F portfolio value decreased from ~$118B to ~$110B this quarter. The top three holdings in the portfolio are MercadoLibre, NVIDIA, and Tesla. There were stake increases in companies such as PDD Holdings, Coupang, and BeiGene, a...

2023-11-13 20:27:00 ET Summary Alnylam Pharmaceuticals experienced significant revenue growth in Q3 2023, driven by collaboration revenues and net product revenues. Financial Health: Strong short-term liquidity with a current ratio of 3.1, but higher liabilities ($4B) than assets ...

2023-11-13 09:17:37 ET More on Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2023 Earnings Call Transcript Alnylam Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vut...

– Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Placebo-Adjusted Reduction of 24-Hour Mean Systolic Blood Pressure at Three Months of Treatment – – Study Met Key Secondary Endpoints Showing Consistent and Sustained Reductions of Systolic Blood Pressur...

2023-11-08 11:27:49 ET Summary VIR took a big hit in July with the failure of the company's trial in influenza, but the stock has continued to slide since. A new BARDA contract to develop a COVID antibody and another drug against a pathogen with pandemic potential has failed to li...

2023-11-02 11:58:05 ET Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2023 Earnings Conference Call November 02, 2023, 08:30 AM ET Company Participants Christine Lindenboom - Senior Vice President-Investor Relations and Corporate Communication Yvonne Greenstreet - Chief Exe...

2023-11-02 08:05:05 ET More on Alnylam Pharmaceuticals Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One Alnylam: Why The FDA Rejection Of Onpattro Is A Minor Set...

− Achieved Third Quarter 2023 Global Net Product Revenues of $313 Million, Representing 35% Year-Over-Year Growth Compared to Q3 2022 – − Received Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardi...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...